More than 1,400 adults participated in Novo Nordisk’s phase 3 trial, which included lifestyle interventions such as reduced calorie intake and increased physical activity. Participants were divided into three groups: one receiving a placebo, another receiving 2.4-milligram injections (the highest currently approved dose), and a third receiving 7.2-milligram injections.
At the start of the 72-week study, participants’ mean body weight was approximately 250 pounds. Adults in the 7.2 milligram group experienced an average 18.7% weight reduction, compared to 15.6% in the 2.4 milligram group and 3.9% in the placebo group.
With perfect adherence to the regimen, researchers estimated weight loss would be 20.7% for the 7.2 milligram group, 17.5% for the 2.4 milligram group and 2.4% for the placebo group.
Novo Nordisk announced the study results on Jan. 17 and stated that additional findings will be presented at a scientific conference in 2025.
